SFNCL 2026
Spineway Group is pleased to announce its participation in the annual conference of the French Society of Private Practice Neurosurgeons (SFNCL), to be held on September 26, 2026, in Marseille.
You are about to be redirected to https://example.com. Do you want to continue?
Spineway Group is pleased to announce its participation in the annual conference of the French Society of Private Practice Neurosurgeons (SFNCL), to be held on September 26, 2026, in Marseille.
Read more
Spineway Group will participate in WHX Dubai 2027, one of the largest international events in the healthcare sector, to be held at the Dubai Exhibition Centre, Expo City.
Read more
Continued growth - Stable results - Strong embedded growth drivers - Issuance of straight bonds to finance future growth
Read more
SPINEWAY, a specialist in innovative implants for the treatment of severe spine disorders, is once again participating in the 2026 Annual Congress of the French Spine Surgery Society (SFCR), to be held from June 11 to 13 at the Palais du Pharo in Marseille.
Read more
High order volume / Slower-than-expected normalization of supply chains / 2026: growth trajectory confirmed
Read more
The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Thursday 2 April 2026 at 10.00 am at the company’s registered office, 7 allée Moulin Berger in Ecully (69).
Read more
Le groupe Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a organisé jeudi 19 mars un webinaire au cours duquel, Stéphane Le Roux, PDG de Spineway, et Erwan Martin, Directeur financier, ont présenté les résultats annuels 2025 et les perspectives du Groupe.
Read more
Read more
In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders deferred from the first half of the year. With revenue of €3.8 million, up 34% compared with Q4 2024 (€2.8 million), Spineway recorded a particularly dynamic fourth quarter.
Read more
The information provided on the following pages is exclusively intended for healthcare professionals. By clicking here you certify being a healthcare professional.